HERMES PHARMA, previously a division of HERMES Arzneimittel GmbH, has formed a separate legal entity named HERMES PHARMA GmbH and both will operate independently but remain part of the Johannes Burges Family Foundation. The move marks a new phase for HERMES PHARMA bringing greater independence while retaining long-term stability for the company’s third-party business.
 
HERMES PHARMA, a CDMO, specializes in the development and manufacture of user-friendly oral dosage forms for healthcare companies around the world. Services cover the entire pharmaceutical value chain – from new product development through to manufacturing and regulatory support. As a division, HERMES PHARMA has continued to see steady growth over the last 20 years. Annual turnover has increased sevenfold, achieving more than €140 million in 2020, and the division has quadrupled the size of its team.
 
Dr. Thomas Hein, Senior Vice President Commercial & Regulatory Affairs, said, “Becoming an independent company will provide HERMES PHARMA with increased flexibility, making us more agile in our management decisions. We will be able to focus our investments to best meet the needs of our customers, whether that’s through new technology, enhanced sustainability, or optimized supply agreements. We highly value our long-term customer relations, which we regard as a strategic asset, and look forward to a long future of open and trust-based partnerships.”
 
HERMES PHARMA GmbH will move forward with the existing management team in place. Dr Andreas Schrepfer, Managing Director, said, “HERMES Arzneimittel has a long history of pharmaceutical excellence – more than 100 years, in fact. This reorganization is part of a long-term strategy that will build on our heritage and position us to foster future growth. Remaining in the Johannes Burges Family Foundation will help ensure our financial stability.”